Management of antimicrobial use in the intensive care unit

Drugs

Volumn 61, Issue 6, 2001, Pages 763-775

  Alvarez Lerma F ^a   Palomar, M ^b   Grau, S ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFONICID; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; MACROLIDE; MEROPENEM; METRONIDAZOLE; OFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G SODIUM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CRITICAL ILLNESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; GEOGRAPHIC PATHOLOGY; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; MONOTHERAPY; NONHUMAN; PATIENT MONITORING; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; TREATMENT PLANNING;

BACTERIA (MICROORGANISMS); PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0034985570     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00005     Document Type: Review

References (64)

1. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study
2. Nosocomial infections in Spain: Results of 5 nationwide serial prevalence surveys (EPINE Project, 1990 to 1994)
3. Antibiotic usage patterns and trends in Spanish Intensive Care Unit (ICUs)
4. Aerosol polymyxin and pneumonia in serious ill patients
5. Emergence of gentamicin- and carbenicillin-resistant Pseudomonas aeruginosa in a hospital environment
6. Changes in aerobic faecal bacterial flora of severely ill patients during antibiotic treatment
7. Emergence of resistance in Gram-negative bacteria during therapy with extended-spectrum cephalosporins
8. Antibiotic resistance associated with selective decontamination of the digestive tract
9. Epidemiological impact of prolonged systematic use of topical SDD on bacterial colonization of the tracheobronchial tree and antibiotic resistance. A 3 year study
10. Problems in antibiotic usage
11. Antibiotic usage in an intensive care unit in a Danish university hospital
12. Antibiotic treatment for surgical peritonitis
13. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
14. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among criticlly ill patients
15. Optimal use of modern antibiotics: Emerging trends
16. The pharmacodynamics of aminoglycosides
17. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
18. The pharmacodynamics of beta-lactams
19. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with impipenem-cilastatin
20. Recurrent Pseudomonas aeruginosa pneumonia in a intensive care unit
21. Ventilator-associated pneumonia due to Pseudomonas aeruginosa
22. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients
23. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
24. An overview of mortality risk prediction in sepsis
25. ICU infections in Spain. Time trends of etiology and resistances from 1994 to 1998
26. Severe community-acquired pneumonia in the elderly: Epidemiology and prognosis
27. Nosocomial bacteremia in critically ill patients: A multicenter study evaluating epidemiology and prognosis
28. Etiology and diagnostic techniques in intensive care acquired pneumonia
29. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risk associated with different antipseudomonal agents
30. The value of surveillance cultures in neonatal intensive care units
31. Classification on infections
32. Evaluation of vancomycin for therapy of adult pneumococcal meningitis
33. Penetration of antibiotics into respiratory secretions
34. Human pancreatic tissue concentration of bactericidal antibiotics
35. Actividad antianaerobicida de los carbapenemicos
36. Damage to bacteria by antibiotics in vitro and its relevance to antimicrobial chemotherapy: A historical perspective
37. Once daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious infections: Comparative trial with netilmicin plus ceftriaxone
38. Once versus thrice daily gentamicin in patients with serious infections
39. Experience with a once-daily aminoglycoside program administered to 2,184 adults patients
40. Once-daily aminoglycoside dosing in immunocompentent adults: A meta-analysis
41. Single or multiple daily doses of aminoglycosides: A meta-analysis
42. Single daily doses of aminoglycosides
43. Clinical pharmacokinetics of continuous intravenous administration of penicillins
44. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents
45. Pharmacodynamics of intermitent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model
46. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime
47. Pharmacokinetics of ceftazidime in adult cystic fibrosis during continuous infusion and ambulatory treatment at home
48. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia
49. Continuous infusion of vancomycin in methicillin- resistant staphylococcus infection
50. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections
51. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococal sepsis
52. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: Comparison of aerosol and systemic administration
53. Double-blind study of endotracheal tobramycin in the treatment of Gram-negative bacterial pneumonia
54. Nosocomial gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen
55. The therapeutic monitoring of antimicrobial agents
56. A pharmacokinetic model-independent approach for estimating dose required to give derived steady-state trough concentrations of drug in plasma
57. Impacto de las resistencias bacterianas sobre la politica antibiótica
58. New intervention strategies for reducing antibiotic resistance
59. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance
60. Decalogo de normas para la utilización de antibióticos en pacientes críticos
61. Why don't physicians follow practice guidelines? A framework for improvement
62. Monitoring of antimicrobial therapy by an integrated computer program
63. A computer-assisted management program for antibiotics and other antiinfective agents